Inhibrx Biosciences, Inc. — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Inhibrx disclosed interim Phase 2 HexAgon trial data for INBRX-106 (hexavalent OX40 agonist) combined with pembrolizumab in first-line recurrent/metastatic head-and-neck squamous cell carcinoma (HNSCC). In HPV-positive patients (n=10 combo vs n=9 mono), combination achieved 80% confirmed objective response rate versus 33% for pembrolizumab alone, with 90% vs 33% progression-free survival at 6 months. The company plans to expand Phase 2 enrollment by 50 additional HPV+ patients, targeting potential accelerated approval by end of 2028/early 2029. INBRX-109 (ozekibart, DR5 agonist) achieved primary endpoint in chondrosarcoma with HR=0.479 (P=0.0001), more than doubling median PFS to 5.52 vs 2.66 months; anticipated approval and commercial launch in 2H 2027.
Why this rating
INBRX-106 data materially strengthens lead candidate; HPV+ signals support accelerated path and $4B+ market. Chondrosarcoma approval near. Company ~$175M market cap; meaningful catalysts ahead. However, early-stage Phase 2 data, small sample sizes, and regulatory path uncertain. Significant but not transformational yet.
Tradability signal
NO TRADE
No trade: already up 5.4% on the news and the fade evidence is too weak. Similar past filings (53 in this cell) moved +0.37% in the called direction over 4 hrs; shrunk for sample size that's a +0.25% edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $101.71 ▼ 4.15% | at our read · unknown $106.11 | +10 min · unknown $106.23 ▲ 0.11% | +30 min · unknown $104.18 ▼ 1.82% | +1 hr · unknown $104.39 ▼ 1.63% | +4 hrs · unknown $103.97 ▼ 2.02% |
The stock had already moved +4.33% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.